



12th SABPA Education and Career Development Event



Education and Career Development Committee
Cordially Invite You and Your Guest to

Leadership in the Changing World

Speakers

Dr. Yuan Xu

Vice President and Head,
Biotherapeutics Development Unit, Novartis

Mr. Brian O'Callaghan

President and Chief Executive Officer,
Sangart Inc.

Saturday, April 6, 2013, 11:30 am - 2:00 pm

Knobbe Martens

da Vinci Conference Center/Auditorium

12790 El Camino Real

San Diego, CA 92130

Registration (www.sabpa.org)

\$10 (\$5 student) online by April 3rd

\$20 onsite (\$10 students onsite)

Program

- 11:30 am - Registration & Networking
- 12:00 pm - Light lunch
- 12:30 pm - Welcome: David Jiang, Ph.D., MBA, Chair, ECD Committee, SABPA;
Managing Director, BIOCUM China Consulting
- 12:35 pm - Speaker Introductions
- 12:40 pm - Yuan Xu, Ph.D., Vice President and Head, Biotherapeutics Development Unit,
Novartis
- 1:05 pm - Brian O'Callaghan, President and CEO, Sangart Inc.
- 1:30 pm - Q&A
- 1:55 pm - Wrap-up & SABPA Upcoming Events

Speaker Biographies

Yuan Xu, Ph.D.

Dr. Yuan Xu is currently the Vice President and Head of Biotherapeutics Development Unit co-located at Novartis La Jolla site. She previously served as Global Head and VP of Process Sciences, Production and Quality at Novartis Biologics, and VP and Site Head for Novartis Biologics at Basel Site from 2008 to 2011. Prior to joining Novartis, Dr. Xu held leadership positions, with increasing responsibilities, at several Biotech and Pharmaceutical Companies including Genentech, GlaxoSmithKline, Chiron Corporation, and Amgen. Dr. Xu has worked on many biotherapeutics including various forms of antibodies, recombinant proteins, antibody-drug conjugates, therapeutic vaccines, gene and cell therapies. Dr. Xu has extensive scientific/technical expertise and development/regulatory experience with multiple successful biotech products including Activase, Pulmozyme, Rituxan, Herceptin, TNKase, Xolair, Raptiva, Avastin, Lucentis, Bexxar, Bacaplemin, Proleukin, Epogen, Enbrel, Prolia, Extavia and Ilaris. Dr. Xu performed Postdoc training in Molecular Virology and Gene Therapy from University of California at San Diego Medical School. Dr. Xu has a Ph.D. in Protein Biochemistry from the University of Maryland at College Park and a B.S. in Biochemistry and Molecular Biology from Nanjing University in China.



Brian O'Callaghan

Mr. Brian O'Callaghan joined Sangart as President and Chief Executive Officer in June 2008. Mr. O'Callaghan brings a breadth of experience to Sangart, having held senior positions with a number of pharmaceutical and biotechnology companies in both Europe and the US. These include senior positions with Pfizer in the UK and Merck Serono in Germany, before becoming President and CEO of BioPartners, a Swiss based biotechnology company. Since relocating to the US, Mr. O'Callaghan has held senior management positions at Novartis, where he served as General Manager of their Transplantation, Immunology and Infectious Disease businesses, as well as at Covance, a clinical research firm, where he served as General Manager of their Cardiac safety and IVRS businesses. Mr. O'Callaghan joins Sangart from NPS Pharmaceuticals, where he served as Chief Commercial Officer. Mr. O'Callaghan brings his extensive general management background in the pharmaceutical, biotechnology and clinical research sectors, as well as his significant international experience, to lead Sangart through regulatory submission and commercial launch of MP4. Last October, Mr. O'Callaghan led a senior executive team to visit 9 Chinese companies in 5 cities to explore potential partnership opportunities.

